￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
Menu

Medical drugs

Medical drugs-Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Who is not suitable for taking aprocitentan and what are its contraindications?

2026-02-01 22:25:32

Check Details
Can Tilpotide/Tisiparatide (Mufenda) be stopped suddenly and what precautions should be taken after stopping the medicine

2026-02-01 22:25:32

Check Details
Description of the medical insurance process and reimbursement time points for pitobrutinib/pirtobrutinib

2026-02-01 22:25:32

Check Details
Risk analysis of whether talazoparib (Tazena) can be stopped at will after taking it

2026-02-01 22:25:32

Check Details
Whether Crizotinib has been included in critical illness insurance and reimbursement policies

2026-02-01 22:25:32

Check Details
Aprocitentan drug introduction and comprehensive analysis of indications and efficacy

2026-02-01 22:25:32

Check Details
Analysis of the risk of blood sugar or weight rebound after discontinuation of tilpotide/tirsiparatide (Mufenda)

2026-02-01 22:25:32

Check Details
Analysis of the long-term safety and treatment duration of Pitobrutinib/Pitobrutinib (Jepali)

2026-02-01 22:25:32

Check Details
The efficacy of talazoparib (Tazena) in patients with prostate cancer TP gene mutation

2026-02-01 22:25:32

Check Details
Crizotinib price decline and interpretation of market reference information

2026-02-01 22:25:32

Check Details
A safety study on whether aprocitentan can be used in combination with other drugs

2026-02-01 22:25:32

Check Details
Whether Tirzepatide can be reimbursed by medical insurance and cost explanation

2026-02-01 22:25:32

Check Details
Category
相关知识